Major Advances in Gynaecological Cancers 2021
Webinar description
The webinar has been cancelled. We apologize for any inconvenience.
The special live ESGO webinar on July 8, 2021, is designed to offer an overview of the primary clinical trials results on both surgical and medical treatments, and highlight the most significant advances expected in future treatment approaches of gynaecological cancers.
This exclusive webinar will discuss the related key findings and results of selected significant surgical and medical treatment studies presented at conferences this year.

Learning objectives
To get acquainted to the results of major clinical trials and implication of these results in the clinical practice.
Target audience
Gynae-oncologists, medical oncologists, radiation oncologist
Scientific Program
18.30-18.35 Welcome & Opening
18.35-19.00 Improving the Standard of Care: More is NOT Better!
Mansoor Raza Mirza, Denmark
- The OUTBACK Trial / ANZGOG 0902: Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone.
- ENGOT-OV15 / AGO-OVAR 17: Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group.
Immunotherapy: New Era in the Management of Endometrial and Cervical Cancers
Mansoor Raza Mirza, Denmark
- Keynote-775: A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer.
- EMPOWER-CERVICAL 1/GOG-3016/ENGOT-CX9: Interim analysis of phase 3 trial of cemiplimab vs investigator’s choice (IC) chemotherapy (CHEMO) in recurrent/ metastatic (R/M) carcinoma
19.00-19.20 Distillation of SGO 2021 Surgical Practice Abstracts
Nadeem Abu Rustum, USA
19.20-19.30 Q&A









